BusinessRich Pharmaceuticals Explains How Targeted Immunotherapy Aids in the Treatment and Recovery of AML PatientsBy Nasdaq OMXApr 10, 2018, 11:01 AM UTC
BusinessActinium Pharmaceuticals Announces Trial to Study Actimab-A in Combination with CLAG-M for Relapsed or Refractory AML PatientsBy Nasdaq OMXFeb 6, 2018, 12:30 PM UTC
BusinessActinium Pharmaceuticals Announces Positive Preliminary Results from Phase 2 Trial for Actimab-A Highlighted at 59th American Society of Hematology Annual MeetingBy Nasdaq OMXDec 11, 2017, 11:30 AM UTC
BusinessActinium Pharmaceuticals Highlights Strong Presence at 59th Annual American Society of Hematology Meeting Evidenced by Clinical Development Progress and Results Showcasing its AWE Technology PlatformBy Nasdaq OMXNov 29, 2017, 12:32 PM UTC
BusinessActinium Pharmaceuticals Launches the AWE Program aka Actinium Warhead Enabling Program to Enable Collaborations Based on Its Actinium-225 Technology PlatformBy Nasdaq OMXNov 14, 2017, 1:01 PM UTC
BusinessActinium Pharmaceuticals to Host Webcast to Introduce New Clinical Initiative in Collaboration with Leading Hematologist Dr. Gail RobozBy Nasdaq OMXNov 13, 2017, 12:30 PM UTC
BusinessActinium Pharmaceuticals Announces Activation of Fifteenth Clinical Trial Site in the Phase 3 SIERRA Trial for Iomab-BBy Nasdaq OMXOct 25, 2017, 11:30 AM UTC
